Sun, Sep 20, 2026
[Archive]
Volume 16, Issue 4 (9-2026)
Iran J Ped Hematol Oncol 2026, 16(4): 1079-1091 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Alizadehas A, Mahdavi M, Hosseini Jebelli S F, Yalameh Aliabadi A, Afsari zonooz Y, Elahi M, et al . Cardiovascular Complications Due to Treatment Regimens in Pediatric Lymphoma Patients: A Systematic Review. Iran J Ped Hematol Oncol 2026; 16 (4) : 6
URL: http://ijpho.ssu.ac.ir/article-1-921-en.html
URL: http://ijpho.ssu.ac.ir/article-1-921-en.html
Azin Alizadehas 
, Mohammad Mahdavi , Seyedeh Fatemeh Hosseini Jebelli , Azam Yalameh Aliabadi , Yasamin Afsari zonooz , Mohammda Elahi , Maryam Mohseni Salehi , Hoda Hakimian , Golnar Mortaz Hejri *
, Mohammad Mahdavi , Seyedeh Fatemeh Hosseini Jebelli , Azam Yalameh Aliabadi , Yasamin Afsari zonooz , Mohammda Elahi , Maryam Mohseni Salehi , Hoda Hakimian , Golnar Mortaz Hejri *
Congenital Heart Diseases Research Center, Rajaie Cardiovascular Institute, Tehran, Iran & Congenital Heart Diseases Research Center, Rajaie Cardiovascular Institute, Tehran, Iran
Abstract: (9 Views)
Background: Lymphoma is among the most common malignancies in children, and improved survival has increased the importance of treatment-related late effects. Cardiovascular complications may result from the lymphoma itself or from chemotherapy and radiotherapy and can occur during treatment or years after exposure. This systematic review summarizes cardiovascular complications associated with pediatric lymphoma and its treatment.
Materials and Methods: The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework. PubMed, EMBASE, and the Cochrane Library were searched from January 1, 1990, through July 20, 2024. Eligible studies included patients younger than 18 years with Hodgkin lymphoma or non-Hodgkin lymphoma and evaluated cardiovascular complications associated with chemotherapy and/or radiotherapy. Two reviewers independently screened studies, extracted data, and assessed methodological quality. Because of substantial clinical and methodological heterogeneity, findings were synthesized qualitatively.
Results: The search identified 930 records, of which 67 were considered potentially eligible after title and abstract screening. Following full-text assessment, 11 studies met the inclusion criteria. Reported cardiovascular outcomes included cardiomyopathy, ventricular dysfunction, arrhythmias, coronary artery disease, valvular abnormalities, pericardial disease, and other vascular complications. Anthracycline exposure was consistently associated with cardiotoxicity, while mediastinal radiotherapy was associated with important long-term coronary, valvular, and conduction abnormalities. Studies evaluating dexrazoxane suggested a cardioprotective effect without compromising antitumor efficacy.
Conclusion: Cardiovascular complications are an important long-term concern in children and adolescents treated for lymphoma. The available evidence supports risk-adapted cardiovascular surveillance during treatment and long-term survivorship, with particular attention to cumulative anthracycline exposure and mediastinal radiotherapy. Larger prospective studies are needed to define standardized surveillance strategies and clarify the long-term cardiovascular effects of contemporary treatment regimens.
Materials and Methods: The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework. PubMed, EMBASE, and the Cochrane Library were searched from January 1, 1990, through July 20, 2024. Eligible studies included patients younger than 18 years with Hodgkin lymphoma or non-Hodgkin lymphoma and evaluated cardiovascular complications associated with chemotherapy and/or radiotherapy. Two reviewers independently screened studies, extracted data, and assessed methodological quality. Because of substantial clinical and methodological heterogeneity, findings were synthesized qualitatively.
Results: The search identified 930 records, of which 67 were considered potentially eligible after title and abstract screening. Following full-text assessment, 11 studies met the inclusion criteria. Reported cardiovascular outcomes included cardiomyopathy, ventricular dysfunction, arrhythmias, coronary artery disease, valvular abnormalities, pericardial disease, and other vascular complications. Anthracycline exposure was consistently associated with cardiotoxicity, while mediastinal radiotherapy was associated with important long-term coronary, valvular, and conduction abnormalities. Studies evaluating dexrazoxane suggested a cardioprotective effect without compromising antitumor efficacy.
Conclusion: Cardiovascular complications are an important long-term concern in children and adolescents treated for lymphoma. The available evidence supports risk-adapted cardiovascular surveillance during treatment and long-term survivorship, with particular attention to cumulative anthracycline exposure and mediastinal radiotherapy. Larger prospective studies are needed to define standardized surveillance strategies and clarify the long-term cardiovascular effects of contemporary treatment regimens.
Article number: 6
Keywords: Antineoplastic Agents, Cardiovascular Diseases, Drug-Related Side Effects and Adverse Reactions, Lymphoma, Radiotherapy
Type of Study: Review |
Subject:
Heart
Received: 2024/12/27 | Accepted: 2026/09/16 | Published: 2026/09/20
Received: 2024/12/27 | Accepted: 2026/09/16 | Published: 2026/09/20
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
